Fig. 4From: Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspectiveCost-effectiveness acceptability curve. WTPÂ Willingness-to-pay, QALYÂ Quality-adjusted life yearBack to article page